Skip to main content

Cell-based Dx Firm Lophius Biosciences Raises $5.3M

NEW YORK (GenomeWeb News) – T-cell-based diagnostics development firm Lophius Biosciences today announced the closing of a financing round that brought in €4 million ($5.3 million) in funding.

Lophius will use the cash infusion to launch its technologies, it said. VRD and WIC were new investors in the round. Existing investors include S-Refit, HighTech Gründerfonds, Bayern Kapital and two angel investors.

The Regensburg, Germany-based company also announced Ralf Wagner has been named managing director. He will focus on rounding out and launching Lophius' product portfolio. Wagner was founder, CEO, and CSO of GeneArt, which was acquired by Life Technologies in 2010.

Lophius develops T-cell based tests for diagnostic purposes and as possible therapy controls in transplantation, infection, and autoimmune diseases. In 2011, it raised $2 million in a private financing.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.